SCHEMBL12165529

SCHEMBL12165529

Cc1ccccc1Cn1nc2c(N)nc3ccccc3n2c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 9/20 0.56
▸ ADORA2A P29274 9/20 0.56
▸ ADORA1 P30542 5/20 0.56
▸ NPC1 O15118 1/20 0.47
▸ GALR3 O60755 1/20 0.47
▸ NR2F2 P24468 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ASAH1 Q13510 1/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12165845 0.90 ADORA2A (0.51) ADORA3ADORA2AADORA1NPC1GALR3
SCHEMBL16065954 0.89 ADORA3 (0.55) ADORA3ADORA2AADORA1MEN1KMT2A
SCHEMBL12165502 0.88 ADORA3 (0.56) ADORA3ADORA2AADORA1
SCHEMBL16065952 0.86 ADORA3 (0.56) ADORA3ADORA2AADORA1RAB9AMEN1
SCHEMBL12165501 0.86 ADORA3 (0.54) ADORA3ADORA2AADORA1
SCHEMBL12188014 0.85 ADORA3 (0.55) ADORA3ADORA2AADORA1RAB9AMEN1
SCHEMBL12165600 0.85 ADORA2A (0.41) ADORA3ADORA2AADORA1NPC1GALR3
SCHEMBL12165745 0.84 ADORA3 (0.50) ADORA3ADORA2AADORA1NPC1RAB9A
SCHEMBL14922472 0.84 ADORA3 (0.50) ADORA3ADORA2AADORA1CYP1A2CYP2C19
SCHEMBL12655143 0.84 ADORA3 (0.52) ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435994-B2 Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 — — US disclosed
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed
WO-2011060207-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY SCHERING CORPORATION (US) 2011-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback